Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, angiotensin II (Giapreza®) cannot be endorsed for use within NHS Wales for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies |
||
|
||
Medicine details |
||
| Medicine name | Angiotensin II (Giapreza®) | |
| Formulation | 2.5 mg/ml concentrate for solution for infusion | |
| Reference number | 3500 | |
| Indication | For the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies |
|
| Company | La Jolla Pharmaceutical | |
| BNF chapter | Cardiovascular system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 13/12/2019 | |